EA201692471A1 - Антиретровирусное лекарственное средство, нацеленное на эндогенный ретровирус человека - Google Patents

Антиретровирусное лекарственное средство, нацеленное на эндогенный ретровирус человека

Info

Publication number
EA201692471A1
EA201692471A1 EA201692471A EA201692471A EA201692471A1 EA 201692471 A1 EA201692471 A1 EA 201692471A1 EA 201692471 A EA201692471 A EA 201692471A EA 201692471 A EA201692471 A EA 201692471A EA 201692471 A1 EA201692471 A1 EA 201692471A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antiretroviral
herv
endogenous human
antibody
human retrovirus
Prior art date
Application number
EA201692471A
Other languages
English (en)
Other versions
EA034612B1 (ru
Inventor
Эрве Перрон
Франсуа Кюртен
Алоис Ланг
Рафаэль Фокар
Жюли Медина
Александра Мадейра
Надеж Жеэн
Original Assignee
Женёро Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Женёро Са filed Critical Женёро Са
Publication of EA201692471A1 publication Critical patent/EA201692471A1/ru
Publication of EA034612B1 publication Critical patent/EA034612B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Изобретение относится к антителу, его фрагменту или производному для применения в качестве антиретровирусного лекарственного средства, направленного на вирус, принадлежащий к эндогенным ретровирусам человека W-типа (HERV-W), где указанное антитело, фрагмент или его производное направлены против белка оболочки HERV-W (Env HERV-W). Изобретение также относится к композиции, включающей указанное антитело и лекарственное средство, ингибирующее ретровирусную обратную транскриптазу, для применения в качестве антиретровирусного лекарственного средства, направленного на вирус, принадлежащий к HERV-W.
EA201692471A 2014-05-28 2015-05-27 Комбинация для предотвращения или лечения заболевания, ассоциированного с herv-w, и ее применение EA034612B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305806.3A EP2949342A1 (en) 2014-05-28 2014-05-28 Antiretroviral drug targeting human endogenous retrovirus
PCT/EP2015/061691 WO2015181226A1 (en) 2014-05-28 2015-05-27 Antiretroviral drug targeting human endogenous retrovirus

Publications (2)

Publication Number Publication Date
EA201692471A1 true EA201692471A1 (ru) 2017-04-28
EA034612B1 EA034612B1 (ru) 2020-02-27

Family

ID=50976559

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692471A EA034612B1 (ru) 2014-05-28 2015-05-27 Комбинация для предотвращения или лечения заболевания, ассоциированного с herv-w, и ее применение

Country Status (24)

Country Link
US (2) US20170101461A1 (ru)
EP (2) EP2949342A1 (ru)
JP (1) JP2017519815A (ru)
KR (1) KR20170012376A (ru)
CN (2) CN106536550A (ru)
AR (1) AR100642A1 (ru)
AU (1) AU2015265936B2 (ru)
BR (1) BR112016027671B8 (ru)
CA (1) CA2949884C (ru)
DK (1) DK3148582T3 (ru)
EA (1) EA034612B1 (ru)
EC (1) ECSP16091728A (ru)
ES (1) ES2752131T3 (ru)
HU (1) HUE046187T2 (ru)
IL (1) IL249040B (ru)
MX (1) MX2016015560A (ru)
PL (1) PL3148582T3 (ru)
PT (1) PT3148582T (ru)
RU (1) RU2689326C1 (ru)
SG (1) SG11201609886SA (ru)
TW (1) TW201625679A (ru)
UA (1) UA120274C2 (ru)
WO (1) WO2015181226A1 (ru)
ZA (1) ZA201608050B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018028538A (ja) * 2016-08-12 2018-02-22 公立大学法人名古屋市立大学 統合失調症とその関連疾患の診断用マーカー及びその使用
WO2019201908A1 (en) 2018-04-17 2019-10-24 Geneuro Sa Method for the detection of the soluble hydrophilic oligomeric form of herv-w envelope protein
EP3916015A1 (en) 2020-05-28 2021-12-01 Geneuro SA Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893691A1 (en) * 1997-07-23 1999-01-27 Mach, Bernard François, Prof. Methods for diagnosis and therapy of autoimmunedisease, such as insulin dependent diabetes mellitus, involving retroviral superantigens
FR2791140B1 (fr) * 1999-03-19 2002-03-22 Bio Merieux Procede de detection d'une activite superantigenique dans un echantillon et composition therapeutique ou prophylactique
CA2461290C (en) * 2001-09-24 2014-11-25 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
FR2865403B1 (fr) * 2004-01-23 2009-06-12 Biomerieux Sa Composition pour le traitement d'une pathologie associee a la msrv/herv-w
FR2912314B1 (fr) * 2007-02-09 2012-08-03 Geneuro Sa Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.
MX2010014319A (es) * 2008-07-08 2011-05-19 Geneuro Sa Uso terapeutico de ligando especifico en enfermedades asociadas con msrv.
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
UA119032C2 (uk) * 2012-10-02 2019-04-25 Женеро Са Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w

Also Published As

Publication number Publication date
AR100642A1 (es) 2016-10-19
AU2015265936B2 (en) 2020-07-30
HUE046187T2 (hu) 2020-02-28
PL3148582T3 (pl) 2020-06-15
SG11201609886SA (en) 2016-12-29
BR112016027671A2 (pt) 2018-01-30
EP2949342A1 (en) 2015-12-02
EP3148582A1 (en) 2017-04-05
ZA201608050B (en) 2020-05-27
ES2752131T3 (es) 2020-04-03
US20170101461A1 (en) 2017-04-13
KR20170012376A (ko) 2017-02-02
WO2015181226A1 (en) 2015-12-03
EA034612B1 (ru) 2020-02-27
PT3148582T (pt) 2019-11-04
AU2015265936A1 (en) 2016-12-15
IL249040B (en) 2020-05-31
CN114276444A (zh) 2022-04-05
IL249040A0 (en) 2017-01-31
JP2017519815A (ja) 2017-07-20
EP3148582B1 (en) 2019-07-31
BR112016027671B8 (pt) 2024-01-09
MX2016015560A (es) 2017-07-13
DK3148582T3 (da) 2019-10-28
UA120274C2 (uk) 2019-11-11
CN106536550A (zh) 2017-03-22
ECSP16091728A (es) 2017-06-30
US20190263895A1 (en) 2019-08-29
US10894820B2 (en) 2021-01-19
TW201625679A (zh) 2016-07-16
BR112016027671B1 (pt) 2023-11-21
RU2689326C1 (ru) 2019-05-27
CA2949884C (en) 2023-09-05
CA2949884A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
BR112016017046A2 (pt) Anticorpos contra glicoproteína f de vírus hendra e nipah
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
EA201692471A1 (ru) Антиретровирусное лекарственное средство, нацеленное на эндогенный ретровирус человека
CL2019003167A1 (es) Proteínas de unión al antígeno anti-jagged1.
EA201892085A1 (ru) Новые белки, полученные из альфа-1-микроглобулина, и их применение
BR112018012922A2 (pt) fórmula infantil que compreende peptídeos de leite humano
BR112017005993A2 (pt) derivados de peptídeo inovadores e usos dos mesmos
BR112017003252A2 (pt) terapia com anticorpos contra hiv como substituto de tratamento
CL2016002361A1 (es) Compuestos derivados de azabenzofurano; composición farmacéutica, y su uso como inhibidores de la función de la proteína ns5b del hcv para el tratamiento de la hepatitis c.
CY1122445T1 (el) Ανταγωνιστες διαυλου καλιου kv1.3
EA201990042A1 (ru) Композиции, содержащие тимолол и противовоспалительное средство
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении
AR107012A1 (es) ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A ErbB3 Y EL USO DEL MISMO
TH170374A (th) "ยาต้านเรโทรไวรัสที่มีเป้าหมายเป็นเอนโดจีเนียสเรโทรไวรัสมนุษย์"
TH170374B (th) "ยาต้านเรโทรไวรัสที่มีเป้าหมายเป็นเอนโดจีเนียสเรโทรไวรัสมนุษย์"
TR201402220A2 (tr) Hemaglütinin esteraz baskılama niteliği sergileyen pikroretosit türevlerini ihtiva eden bir kompozisyon ve bu kompozisyonun viral enfeksiyonların tedavisinde kullanımı.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM